Open AccessPrevalence of familial hypercholesterolemia in Attica region, Greece
Author(s) -
Niki Pavlatou,
Νikoletta Ρovina,
Georgia Toylia,
Όλγα Καδδά,
Christina Marvaki,
Theodore Kapadohos,
Genovefa Kolovou,
Antonia Koutsoukou
Publication year - 2021
Publication title -
health and research journal
Language(s) - English
Resource type - Journals
ISSN - 2459-3192
DOI - 10.12681/healthresj.26096
Subject(s) - familial hypercholesterolemia , medicine , body mass index , demography , disease , blood pressure , cholesterol , sociology
Background: Dyslipidemias are one of the major modifiable risk factors for cardiovascular disease. Familial hypercholesterolemia (FH) is the most common genetic metabolic disorder; it is estimated that around 14-34 million people worldwide have FH but only 25% of FH patients have been diagnosed. Aim: The aim of the present study was to explore the prevalence of FH in Attica region, Greece.Methods: Attica region was divided into 8 regional units. A predesigned questionnaire was used to collect demographic and clinical data. Data analysis was performed by using the Statistical Package for the Social Sciences (SPSS), ver. 20.Results: The studied sample consisted of 1578 Greek inhabitants of Attica region. The majority of the sample was women (59.9%). The mean age of the studied participants was 47.1 (±14.9) years. According to Simon Broome criteria, the probability of an FH diagnosis as unlikely is determined in 98.7% of the studied sample, probable in 0.8% of the participants or definite in 0.5% of the participants, based on this data, the prevalence of FH in Attica region, Greece is 1:200. Qualitative factors found to be associated with the onset of the disease were medication (p-value = 0.001) and hypolipidemic therapy (p-value = 0.001). The quantitative factors found to be associated with disease onset were body mass index (p-value = 0.044), and systolic (p-value = 0.001) and diastolic (p-value = 0.007) pressure.Conclusions: Based on our data, the prevalence of FH in Attica region, Greece is 1:200. Early identification of contributing factors in FH development and proper treatment is vital and reduce the risk of premature and severe atherosclerotic disease.